Clinical Trial Update: AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

This report summarizes Phase 1 trial results for AMP-224, a PD-1 inhibitor, in combination with stereotactic body radiation therapy for metastatic colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• AMP-224

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Cancer, Colorectal Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-02-22